Transcript TFP Measurement of Korean Firms

2012 Fall Seminar on Technology Strategy
Competitive advantages from in-house
scientific research: The US pharmaceutical
industry in the 1980s
Gambardella, A. (1992), Research Policy, 21(5), 391-407
2012. 9. 24
박사과정 4학기 한상연
Ⅰ. Summary(1)

Science as a public goods
 firms can take advantage at no cost of the information produced
by academia and other non-profit research institutions.

The role of in-house scientific research
 a means of absorbing external knowledge( Cohen and Levinthal, 1989)
 the price to plug into the outside information network(Rogenberg, 1990)

Focus of Paper
 explores whether, in spite of the public nature of science, large US drug
manufacturers have differed in their ability to exploit the public good
2
Ⅰ. Summary(2)

The firms in the case studies
 Merck : an internal organization of research that resembles academic
departments or other scientific institutions
- peer group evaluation, using external basic research results
 Eli Lilly : investing both in equipment, and in learning the new technique
from Agouron
 Bristol-Myers/Squipp : shifting to research-oriented group
- comprehensive agreement with Yale University
- acquired genetic systems and Oncogen, specialized in biotechnology
 SmithKline : late R&D Investment and late performance, Tagamet
- Restructuring in R&D after entering competitor Glaxo’s Zantac
 Rorer : Too short periods to invest more R&D
- aggressive strategy to increase the R&D, acquired by Rhone-Poulene
3
Ⅰ. Summary(2)

Test of interfirm differences in exploiting public science
Company patents are positively correlated with the scientific publications
of the firms
4
Ⅱ. Discussion(1)

The effectiveness of Catch-up Strategy
 What does the strategy of Samsung Biologic resemble firms’ one in our
paper?
 In the respective of papers in this session, discuss and predict the validity of
Samsung’s strategies
- technology sourcing, cooperation, Joint-Venture, transferring of Informal
Knowledge
5
Ⅱ. Discussion(2)

The Classification and Segmentation of R&D capability
 What’s the difference between Capability of in-house research and
Absorptive Capacity?
 Following the diffusion of Open innovation economy, except capability of
R&D in itself and internalization,
what Is the other capability for innovation of firms?
- focus the ability to investigate the exact demand knowledge
 In the point of this paper and others, the strategy of Samsung can not be
effective due to lack of current R&D capability. What are your views on that?
6
Tessa C. Flatten, Andreas Engelen , Shaker A. Zahra , Malte Brettel (2011), A measure of
absorptive capacity: Scale development and validation, European Management Journal , 29, 98–
116
7
Thank You!